The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dumbpunter - one might argue that every phase II trial is inconclusive as it is conducted on a relatively small sample but it can give us a (very) strong indication of the drug/compound potential. That is precisely why there is Phase III, to hopefully further validate that. Of course there is still risk, I'd hope that everyone on this board is well aware of that and has factored that risk in. I believe SNG have published results that are true, accurate and very promising - I do not doubt their integrity and 79% efficacy is truly impressive. You mentioned Venrock are reducing their holding as results are inconclusive. Results were published 3 months ago, have they just found out something new that they have not been aware of? BTW, I completely understand why you are reducing your position if it is half of your pension fund, that'd be too risky for me too.
Fair play Dumb, risk is a personal choice and I respect yours. I will be sorry to no longer see you involved here. Best of luck to you.
What you on about Doc? How can P2 possibly be labelled anything other than a success? What other clinical covid trials have delivered better results in such a short time frame? Utter Rubbish
So you don't think raising 80 million in a depressed market is a fair pointer to where this is going be interesting to see what you put together
Dumb, I’m a little confused. You used to write some really insightful posts with your pharma background. On October 21 Oct you posted
“Long term investors take part in the placing, not reduce their holdings.”
Then you reduce your holding. Now everything you write is negative. Are you hoping to get back in below 178?
So, you still hope for the best :) I mean, you still have 5k riding on the success of SNG. Good man!
@bobbybingo : I don't think we'll know until they publish the full trial details. But it's hard to see why they wouldn't.
Sgd27
Thanks that is positive , do we know if a monitoring committee will be set up? as if not then we might not know anything until the end of the trial which would be very annoying
Dumbpunter, are you a SNG holder at the moment?
@bobbybingo : A double-blind trial can be stopped early if they have set up an independent Data Monitoring Committee, and this committee sees overwhelming benefit. Here is an example from just a few months ago :
https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/farxiga-ckd-trial-early-stop-for-positive-efficacy/202003300700070048I/
Graham201986,
This is from Parexel who are running the trial and they state that it is a double blind trial, this seems different from opinions on here so can this be the wrong from Parexel as if it is indeed a double blind trial then would this not make a large difference to being able to stop for benefit or have live data available? thoughts on this anyone?
Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to
accelerate recovery among hospitalized patients receiving oxygen. The randomized, doubleblind,
placebo-controlled trial is expected to enroll 900 patients across approximately 20
countries.
It's worth mentioning that it is very difficult to quantify commercial potential of thisnproduxt as it is a treatment for Covid but also a broad sprectrum antiviral for potentially any chest infection and a potential prophylactic for patients with comorbidities in flu season (as it has also shown efficacy in tandem with steroids).This could go into billions, very difficult to predicts
Remember this is not a double blind trial. If the results of P2 are being replicated early in P3 this will have an EUA issued immediately. The regulators will all have access to the live data. Be under no illusion this may still be in every hospital before Xmas. It would be unethical to continue with the trial and have patients on placebo if P2 data is mimicked. I believe this is why the trial is not a double blind.
Positive results from Phase II , current SP, general COVID state of play, lack of immunity, vaccine availability is uncertain, vaccine doubters, vaccine efficacy, potential emergency approval prior to conclusion of phase III.
I sold out of NCYT yesterday, I held on 3 separate occasions making 65%, 25% and 25% profit - nowhere near as some others but better than the bank bound offer me.
I looked here after the placing so now holding and hope you are right that this is the next big one. Looking at the lack of immunity it’s going to take testing and treatment to keep the nation safe so I feel treatment is where the next big rises are going to be found.
Inteferon i meant to say my immnology cos im on the PCR too much these days. My apologies
Those that missed NCYT ship this is a no brainer. TNF Beta reduces mortality significantly. So given the situation phase 3 is formality. Even if a vaccine was to come testing for diagnosis will stay, treatment for the sick will stay. Flu vaccines/jabs are given every year but how many people catch and die of it? Common sense. Lets board and take off after RNS before the RNS of FDA approval.